{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:39:27Z","timestamp":1789799967297,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CV185\u2010509"],"award-info":[{"award-number":["CV185\u2010509"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["Jeff Metcalf Internship Program"],"award-info":[{"award-number":["Jeff Metcalf Internship Program"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K24HL141354"],"award-info":[{"award-number":["1K24HL141354"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["University of California, Los Angeles Clinical and Translational Science Institute UL1TR001872"],"award-info":[{"award-number":["University of California, Los Angeles Clinical and Translational Science Institute UL1TR001872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["University of California, Los Angeles Clinical and Translational Science Institute UL1TR001881"],"award-info":[{"award-number":["University of California, Los Angeles Clinical and Translational Science Institute UL1TR001881"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["agsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Direct\u2010acting oral anticoagulants (DOACs), such as apixaban, are the most commonly prescribed anticoagulants, with advantages in that they do not require routine monitoring. However, less frequent contact with healthcare professionals may contribute to poor patient knowledge about potential interactions between over\u2010the\u2010counter (OTC) products and DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Determine the prevalence of use of OTC products (OTC medications and dietary supplements) with potentially serious apixaban interactions and assess patient knowledge of potential interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>Cross\u2010sectional survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING<\/jats:title>\n                    <jats:p>Academic\u2010affiliated outpatient medical practices in northern and southern California.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS<\/jats:title>\n                    <jats:p>A total of 791 English\u2010 or Spanish\u2010speaking patients prescribed apixaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS<\/jats:title>\n                    <jats:p>Use and knowledge of OTC medications and dietary supplements with potentially serious apixaban interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Almost all respondents (n = 771; 97.5%) reported OTC product use. Of respondents, 33% (n = 266) took at least one OTC product with potentially serious apixaban interactions daily\/most days and 53 (6.7%) took multiple products (mean = 2.6 [SD = 2.6]). Aspirin was taken daily by 116 (14.7%; of which 75 [64.7%] also consumed other potentially interacting OTC products), and some days\/as needed by an additional 82 (10.4%). Ibuprofen and naproxen were taken daily\/most days by 14 (1.8%) and occasionally by 225 (28.5%). Dietary supplements with potentially serious interactions were taken daily\/most days by 160 (20.2%). Approximately 66% of respondents were either uncertain or incorrect about the potential for increased bleeding from combining nonsteroidal anti\u2010inflammatory drugs and apixaban. Less knowledge about OTC products with potentially serious interactions was associated with greater OTC product use (odds ratio = 0.54; 95% confidence interval = 0.35\u20100.85).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Significant numbers of patients take OTC products (particularly dietary supplements) with potentially serious interactions with the DOAC apixaban and appear to lack knowledge about potentially harmful interactions. Interventions are needed to educate patients and healthcare providers about potential dangers of taking interacting OTC products in combination with apixaban, and data are needed on outcomes associated with concomitant apixaban\u2013OTC product use.\n                      <jats:bold>J Am Geriatr Soc 68:155\u2013162, 2019<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.16193","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T13:02:50Z","timestamp":1572267770000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prevalence and Knowledge of Potential Interactions Between Over\u2010the\u2010Counter Products and Apixaban"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-6387","authenticated-orcid":false,"given":"Derjung M.","family":"Tarn","sequence":"first","affiliation":[{"name":"Department of Family Medicine David Geffen School of Medicine at UCLA, University of California, Los Angeles  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Division of Geriatrics University of California, San Francisco  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Ramaprasad","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret C.","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine University of California, San Francisco  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice B.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Geriatrics University of California, San Francisco  San Francisco California"},{"name":"Division of Clinical Pharmacology, Department of Medicine and Bioengineering and Therapeutic Sciences University of California, San Francisco  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.05.044"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2017.06.012"},{"key":"e_1_2_6_6_1","unstructured":"U.S. Food and Drug Administration. CYP3A Inducers. 2016.https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/cyp3a-inducers. Accessed September 4 2019."},{"key":"e_1_2_6_7_1","unstructured":"U.S. Food and Drug Administration. Table 2\u20102: Examples of Clinical Index Inhibitors for P450\u2010Mediated Metabolisms (for Use in Index Clinical DDI Studies) (9\/26\/2016).https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/drug\u2010development\u2010and\u2010drug\u2010interactions\u2010table\u2010substrates\u2010inhibitors\u2010and\u2010inducers. Accessed September 4 2019."},{"key":"e_1_2_6_8_1","unstructured":"Xarelto (Rivaroxaban) Full Prescribing Information. Revised August 2019. Available at:http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf. Accessed October 2 2019."},{"key":"e_1_2_6_9_1","unstructured":"Pradaxa (Dabigatran Etexilate Mesylate) Full Prescribing Information. Revised March 2018. Available at:https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf. Accessed October 2 2019."},{"key":"e_1_2_6_10_1","unstructured":"Dietary Supplement Health and Education Act of 1994. Public Law 103\u2010417. 103rd Congress. Approved October 25 1994.http:\/\/ods.od.nih.gov\/About\/DSHEA_Wording.aspx. Accessed September 4 2019."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02391.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007943"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2505"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03967.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0520-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1389-7"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00532.x"},{"key":"e_1_2_6_19_1","unstructured":"Eliquis (apixaban) Full Prescribing Information Contents. Revised 06\/2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202155s012lbl.pdfAccessed September 4 2019."},{"key":"e_1_2_6_20_1","unstructured":"Lexicomp Online.https:\/\/www.wolterskluwercdi.com\/lexicomp-online\/. Accessed September 4 2019."},{"key":"e_1_2_6_21_1","unstructured":"Natural Medicines.https:\/\/naturalmedicines.therapeuticresearch.com\/. Accessed September 4 2019."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0262-1746(87)90055-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655076"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0952-3278(95)90040-3"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00206-3"},{"key":"e_1_2_6_26_1","first-page":"715","article-title":"Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis","volume":"36","author":"Srivastava R","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062174"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.009"},{"key":"e_1_2_6_29_1","first-page":"e177\u2010e232","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett DK","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20578"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.03.020"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2013.01.021"},{"key":"e_1_2_6_33_1","first-page":"48","article-title":"The compliance paradox: what we need to know about \u201creal\u2010world\u201d dietary supplement use in the United States","volume":"13","author":"Thompson JJ","year":"2007","journal-title":"Altern Ther Health Med"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.024"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.5.616"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421090-00004"},{"key":"e_1_2_6_37_1","first-page":"3","article-title":"Behaviors underlying the use of nonvitamin nonmineral dietary supplements in a healthy elderly cohort","volume":"11","author":"Wold RS","year":"2007","journal-title":"J Nutr Health Aging"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2008.0290"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/nem045"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11013-006-9016-0"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9718-z"},{"key":"e_1_2_6_42_1","volume-title":"Consumer Use of Dietary Supplements","author":"Prevention Magazine","year":"2001"},{"key":"e_1_2_6_43_1","unstructured":"Mordor Intelligence. Over the Counter Drugs Market \u2010 Growth Trends and Forecast (2019\u20102024).https:\/\/www.mordorintelligence.com\/industry-reports\/global-over-the-counter-otc-drugs-market-industry. Accessed September 4 2019."}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.16193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.16193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgs.16193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.16193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:48:16Z","timestamp":1762184896000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.16193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/jgs.16193"],"URL":"https:\/\/doi.org\/10.1111\/jgs.16193","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"2019-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}